There are several ways in which pharmaceutical companies or their agents can ADVERTISE products and ENGAGE in conversations via social networks. This survey asks repondents their opinions on best practices.
I've been hearing a lot of criticism of pharma marketing buzzwords lately and wonder what marketing professionals like you think of the many buzzwords commonly used by the pharmaceutical industry today.
This survey is an attempt to understand how pharmaceutical companies and their agencies are using social media listening programs as a part of their marketing and communications programs.
The authors of a #MICEproject research report propose six activities that medical conference organizers should consider in order to draft appropriate future guidelines for third party activities in Twitter backchannels. Tell us YOUR opinion regarding these activities.
Do CME activities that accept commercial support from pharmaceutical companies have more bias that activities that don't?
Results of a 2008 Harris Interactive poll of American attitudes toward corporate America revealed that only 26 percent of Americans view the pharmaceutical industry industry favorably. 52 percent are firmly negative, which places pharma slightly below big oil, and above tobacco. Is the drug industry's bad reputation is deserved? What are the specific reasons why the public has such low esteem for the industry? Take our survey and tell us what you think the industry should do to improve its public image.
Please take a few minutes to tell us your opinion of the future of Direct-to-Consumer (DTC) advertising of prescription medications under a new Democratic Administration.
This survey asked respondents for input on various cost-cutting and ROI strategies available to the pharmaceutical industry, how likely any of these will be adopted in the near future, and what the effect may be upon pharmaceutical marketers.
This survey solicits your opinion on how effective Twitter can be in carrying out patient support activities/communications.
This survey collected comments regarding DTC issues discussed at a November 2005 FDA ipublic hearing.